VERA
Vera Therapeutics, Inc.
Biotechnology · Healthcare · United States
30.98
close · 2026-10-30
value
81
cheaper than peers81
quality
36
stronger fundamentals36
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -7.3% | 79 |
| cash flow yield, 3 years ago | -3.0% | 77 |
| earnings yield, 1 year ago | -8.9% | 75 |
| earnings yield, 3 years ago | -10.8% | 74 |
| cash flow yield, 2 years ago | -4.1% | 73 |
| cash flow yield, 1 year ago | -6.1% | 71 |
| cash flow yield, latest year | -10.8% | 64 |
| earnings yield, latest year | -15.0% | 62 |
| price to book | 5.47× | 26 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -71.3% | 47 |
| debt to equity | 15.4% | 34 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$179.4M |
| employees | 339 |
| first trade | 2021-05-14 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-04 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -4.66 | -2.75 | -2.25 | -3.35 | not reported |
| free cash flow | -$241.7M | -$135.7M | -$92.2M | -$67.7M | not reported |
| net income | -$299.6M | -$152.1M | -$96.0M | -$89.1M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | -$47,000 | -$809,000 | $1.8M |